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Introduction: This prospective study examined association between
circulating plasma DNA, microsatellite alterations (MA), p53 mu-
tations with time to relapse and survival in surgically treated non-
small cell lung cancer (NSCLC) patients (pts).
Methods: Plasma samples, adjacent lung tissue, and lung tumor
tissue specimens were collected from consecutive patients with
stage I–III NSCLC. Blood samples of 66 matched healthy donors
with positive smoking history were collected as controls. The
plasma DNA amount was determined by real-time PCR. The anal-
ysis of MA at loci D3S1300, D3S1289, D3S1266, and D3S2338 on
chromosome 3p was performed by radiolabeled PCR. p53 Mutations
(exons 5, 6, 7, and 8) were detected by PCR-single-strand confor-
mational polymorphism assay.
Results: There were 76 patients, 65 men; median age was 68 years
(range, 42–86), 20 had stage I, 40 stage II, and 16 stage III, the
majority of pts (48.7%) had squamous-cell histology. Sixty-nine
(91%) were smokers and most had good Eastern Cooperative On-
cology Group performance status (0/1:72/4). Mean circulating DNA
of all pts was 60 ng/ml versus 5 ng/ml in smoker-matched controls
(p  0.0001). In pts without recurrence, mean circulating DNA was
48.5 ng/ml at baseline, 32.8 ng/ml at 3rd month, and 20.6 ng/ml at
12th month after surgery. In pts with recurrence, mean circulating
DNA at baseline was 97.1 ng/ml. At 3rd month after surgery, mean
DNA concentration was significantly lower in disease-free pts than
in patients with recurrent disease (32.8 versus 292.7 ng/ml; p 
0.0016). MA in at least one locus was found in 39.5% of NSCLC
tumors. p53 Genomic mutations were observed in 54.0% of tumor
samples. Statistically significant associations were observed be-
tween MA and squamous-cell histotype (p  0.007) and between
p53 mutations and lymph node involvement (p  0.012). MA and
p53 mutations were found to be significantly associated with recur-
rence of disease (p  0.033 and 0.026, respectively).
Conclusion: Our results suggest that MA and p53 mutations in
tumor DNA have a potential prognostic role for disease recurrence
in NSCLC patients, and elevated levels of plasma circulating DNA
identify patients with possible systemic disease at diagnosis. This
might be proposed as an early detection test of disease recurrence.
Key Words: p53, Microsatellite alterations, Quantification plasma
DNA, Non-small cell lung cancer, Prognosis.
(J Thorac Oncol. 2008;3: 365–373)
Non-small cell lung cancer (NSCLC) is a multistep ge-netic disease characterized principally by activation of
proto-oncogenes and inactivation of tumor suppressor
genes.1–3 In most of tumor cells, both alleles of suppressor
genes are inactivated usually by a mutation in one allele and
a deletion of genetic material containing the other allele.
Inactivation of tumor suppressor genes such as p53 and FHIT
is the most frequently identified alteration in human solid
tumors, including NSCLC.4–6 P53 is located at chromosome
17p, which is commonly deleted in lung cancer, and its
alteration occurs at an early stage of lung carcinogenesis.
Deletions of chromosome 3p are found in more than 90% of
lung cancers and span several gene loci, including FHIT at
3p14.2, RASSF1A at 3p21, and ROBO/DUTT1 at 3p12.
Microsatellite analysis has been widely used to detect these
genetic alterations in NSCLC.7–9 Two types of microsatellite
alterations (MA) have been described: loss of heterozygosity
(LOH) and microsatellite instability.10,11 They are probably
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the most frequent genetic changes identified in NSCLC and
are detected in virtually all tumors of lung origin. Recent
studies have shown that MA besides NSCLC may provide
important prognostic information in human cancers including
those of breast, pancreas, and colorectal.12–14 However, most
of these studies were conducted in heavily pretreated, patients
with heterogeneous cancers and stages. Some authors have
evidenced that tumor DNA is detectable in plasma and serum
of patients.15,16 Nanogram quantities of DNA circulating in
blood are also detectable in healthy individuals.17,18 How-
ever, the plasma of cancer patients is enriched in DNA,
containing, on average, about four times the amount of free
DNA, compared with normal controls.17 Since genetic alter-
ations are the basis of NSCLC, we hypothesize that profiles
of MA and the mutations of the p53 gene in early-stage
NSCLC might be correlated with the different biologic be-
haviors of NSCLC and might be used as biomarkers to
predict patient outcome. To test this hypothesis, we designed
a prospective study on patients with NSCLC suitable for
radical surgery. We examined prospectively whether MA,
p53 mutations, and circulating plasma DNA levels both at
diagnosis and at follow-up might be associated with disease-
free survival (DFS) and overall survival (OS) in surgically
treated NSCLC patients.
MATERIALS AND METHODS
Study Population
Consecutive patients undergoing resection for NSCLC
at the Department of Thoracic Surgery, Perugia University
Hospital, Italy, were eligible for this study.
All patients had undergone radical surgery with hilar
and mediastinal lymph node dissection. Histologic subtypes
and grade of differentiation were determined according to by
World Health Organization classification.19 The patients with
lung cancer were staged with CT total body. Mediastinoscopy
was performed in case of left tumors because of the possi-
bility of lymphatic drainage crossing the mediastinum mid-
line, whereas for the right tumors, it was performed only in
cases of uncertain lymph nodal involvement. Postsurgical
pathologic stage was defined according to the Tumor-Node-
Metatasis International Staging System.20
Patients were classified as nonsmokers (never smoker),
current smokers (with an average tobacco consumption esti-
mated at 43 pack-years; range, 20–100), or former smokers
(tobacco consumption stopped from 7.6  4.2 years) with a
previous average tobacco consumption estimated at 47 pack-
years (range, 20–106).
None of the patients received preoperative chemother-
apy or radiotherapy.
The follow-up included a chest radiograph every 6
months and an annual CT of chest and abdomen for the first
3 years. Treatment to relapse was decided individually and
included standard chemotherapy or radiotherapy according to
progression patterns.
The study was reviewed and approved by the institu-
tion’s Ethics Committee and patients had to give their in-
formed consent. Smoker-matched blood donors, classified as
nonsmokers (never smoker), current smokers (with a mean
tobacco consumption estimated at 44 pack-years), or former
smokers (tobacco consumption stopped from 7.2 3.9 years)
with a previous average tobacco consumption estimated at 45
pack-years and were identified through the pools of blood
donors available at participating institution and were consid-
ered as controls.
Sample Collection and DNA Isolation
Immediately after surgical resection, adjacent lung tis-
sue and tumor lung specimens were sampled by the pathol-
ogist and stored at 80°C. Frozen tumors were not micro-
dissected for molecular analyses; only those containing
70% neoplastic cells (assessed from previous H&E frozen
control) were processed for the study. Peripheral blood was
drawn from each patient before surgery and at the 3rd and 12th
month after surgery and collected in lithium-heparin. Plasma
was separated from the cellular fraction by centrifugation at
3500 rpm for 10 minutes at 4°C and then it was frozen at
80°C. DNA was extracted from adjacent lung tissue and
tumor tissues by using the QIAamp tissue kit (Qiagen, Milan,
Italy) according to the tissue protocol. Plasma DNA was
extracted using Qiagen columns (Qiamp Blood Kit, Qiagen
Milan, Italy) according to the protocol for blood and body
fluids; 1 mL of plasma was purified by five passages on the
same column, and the resulting DNA was eluted in 50 l of
sterile bidistilled water and stored at 20°C. Tissue DNA
concentrations were estimated by spectrophotometry.
Microsatellite Analysis
Biologic samples were tested for a set of four micro-
satellite markers at loci located at 3p14.2 (D3S1300, FHIT
locus), at 3p23 (D3S1266), at 3p21 (D3S1289), and at 3p24.2
(D3S2338), considered the most frequent hot-spots of dele-
tions in NSCLC. The sequences of nucleotide markers for
microsatellite analysis are available through the Genome
Database. For PCR amplification, primers of each marker
were end-labeled with [-32P]ATP (4500 Ci/mmol; ICN
Biomedicals, Costa Mesa, CA). PCR amplifications were
performed on 50 ng of tissue DNA in a 25 l volume
containing 3% DMSO, 200 M deoxynucleotide triphos-
phate, 1.5 mM MgCl2, 0.4 M PCR primers including 0.01
M -32P-labeled primer, and 0.5 unit of TaqDNA polymer-
ase (Life Technologies, Inc., Gaithersburg, MD). DNA was
amplified for 35 cycles at 95°C for 30 seconds, 56°C to 60°C
for 60 seconds, and 70°C for 60 seconds, followed by a
5-minute extension at 70°C in a temperature cycler (Strat-
agene) in 500-l plastic tubes. PCR products were separated
on an 8% polyacrylamide-urea-formamide gel and then ex-
posed to x-ray film. The results were interpreted visually by
three independent observers (P.S., L.V., P.L.); discrepancies
were resolved by discussion. For informative cases, allelic
loss (LOH) is scored if the autoradiographic signal of one
allele is reduced approximately 30% in the tumor DNA
compared with the corresponding normal allele by visual
inspection of independent observers. Microsatellite instability
(shift) was defined as the appearance of one or more new
alleles in tumor DNA that was absent in the corresponding
normal DNA. All of the DNA samples with microsatellite
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alterations were amplified twice to rule out PCR artifacts or
sample contamination.
Analysis of p53 Mutations
Using PCR single-strand conformational polymor-
phism analysis, we amplified the conserved exons of the p53
gene, exons 5, 6, 7, and 8. The amplification was performed
on 50 ng of genomic tissue DNA in 25 L, 0.4 M concen-
trations of each primer, 200 M concentrations of de-
oxynucleotide triphosphates, 1 reaction buffer with 3.5 mM
MgCl2, and 1 unit of Taq polymerase (Invitrogen) for exon 5,
0.5 unit for exon 6, and 0.2 unit for exons 7 and 8 of p53. The
reaction mixture was subjected to 38 PCR cycles: 60 seconds
at 94°C; and then 60 seconds at 58°C for exons 5 and 7; 56°C
for exon 6; and 54°C for exon 8 of P53. The denatured PCR
products were electrophoresed on 8% nondenaturing poly-
acrylamide gel at 25 W, for 3 hours at 4°C condition. Gel star
was then immediately performed. Extra bands visualized
opposite normal controls were confirmed as point mutations.
(Figure 1).
DNA Quantification in Plasma
To quantify the circulating DNA in plasma, a real-time
quantitative PCR approach based on the 5 nucleotide method
was used.21,22 Primers and probes were designed to specifi-
cally amplify the hTERT single copy gene mapped on
5p15.33. The amplicon size of the hTERT gene was 98 bp
(position 13059 to 13156, GenBank accession number
AF128893). The sequences of the primers and of the probe
were the following: primer forward, 5-GGC ACA CGT
GGC TTT TCG-3; primer reverse, 5-GGT GAA CCT CGT
AAG TTT ATG CAA-3; probe, VIC5-TCA GGA CGT
CGA GTG GAC ACG GTG-3 TAMRA. Fluorogenic PCRs
were carried out in a reaction volume of 25 l on a GeneAmp
7300 Sequence Detection System (Applied Biosystems).
Each PCR reaction mixture consisted of 5 l of TaqMan
Universal Master Mix (Applied Biosystems), 0.67 l of
probe (15 mmol/L), 0.45 l of primer forward (10 mmol/L),
0.45 l of primer reverse (10 mmol/L), 8.43 l of sterile
water, and 5 l extracted DNA solution. PCR conditions
were as follows: a first denaturation step of 50°C for 2
minutes and then 95°C for 10 minutes, followed by 50
two-step cycles (15 seconds at 95°C; 1 minute at 60°C). Each
plate consisted of patient samples in triplicates and multiple
water blanks as negative control. For construction of the
calibration curve on each plate, we generated a standard
curve using 7-fold serial dilutions of TaqMan Control Human
Genomic DNA (Applied Biosystems) (50, 5, 2.5, and 0.5 ng,
and 250, 50, and 10 pg). Linear amplification down to the last
dilution point representing 10 pg of target DNA was obtained
in each experiment (correlation coefficient, 0.998-0.994;
slope, 3.28-3.36). All of the data were analyzed using the
Sequence Detection System software (Applied Biosystems)
to interpolate the standard amplification curve of DNA at a
known quantity with amplification cycle threshold of the
unknown target sample, thus obtaining the relative amount of
DNA in the experimental sample. For the follow-up study, all
of the consecutive plasma samples for each patient were
simultaneously analyzed in the same real-time PCR experi-
ment to allow comparative quantification of samples along
the observation time.
Statistical Analysis
DFS and OS were described using Kaplan-Meier
curves.
DFS was defined as the time from diagnosis to first
local, regional, or distant relapse, second primary malignancy
or death from any cause, whichever came first. Subjects who
had not recurred or died at the time of the analysis were
censored at the last disease assessment date.
OS was defined as the time from the date of random-
ization to the date of death from any cause. Subjects who
were not reported as having died at the time of the analysis
were censored at the date they were last known to be alive.
Cox’s proportional hazards model was used to assess
the prognostic effect of each studied parameter on OS and
DFS, after adjusting for stage. The capability of plasma DNA
levels to discriminate between cases and controls was as-
sessed by means of receiver operator characteristics (ROC)
curves. ROC analyses plot the sensitivity (i.e., the proportion
of subjects with NSCLC who are accurately classified as
cases based on their plasma DNA levels) and specificity (i.e.,
the proportion of subjects without NSCLC who are accurately
classified as controls based on their plasma DNA levels) for
every possible cut-off level to obtain a curve that represents
the distributional overlap between two groups on a given
measure. By calculating the area under the curve (AUC) of
the ROC, one can derive an index of the performance of a
given measure. Potential AUC values range from 0.0 to 1.0.
An index that is perfectly able to distinguish between two
groups has an AUC value of 1.0, whereas an index in which
groups overlap completely has an AUC of 0.5 (represented by
a diagonal line on the ROC plot).
The 2 or Fisher exact test were used to assess the
association among clinical features, p53 mutations and mic-
rosatellite alterations. Results are expressed as odds ratio and
its 95% confidence interval (95% CI). Comparisons of con-
tinuous variables were performed by means of Student t test
or analysis of variance for repeated measures. Unless other-
wise specified, all tests are with 1 df.
A value of probability 0.05 was considered as statis-
tically significant.
FIGURE 1. Representative MA and p53 mutations of nor-
mal (N) and tissue tumor (T) of NSCLC patients.
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Because of the exploratory nature of the study, no
adjustment of the statistically significant level was applied.
Statistical analysis was performed using SAS (Statisti-
cal Analysis System, SAS Institute Inc., Cary, NC, US,
Version 8.20) software.
RESULTS
Patient Characteristics
From January 2002 to August 2004, 76 consecutive
patients with stage I–III NSCLC, suitable for surgery, were
recruited. Histologic diagnosis was confirmed independently
by two pathologists at the Institute of Pathology, University
of Perugia, Italy. The following resections were performed: 2
wedge resections (2.6%), 66 lobectomies (86.8%), and 8
pneumonectomies (10.6%).
Sixty-five of 76 patients (85%) were males with a
median age of 68 years, ranging from 42 to 86. Sixty-nine
(91%) were smokers and had mainly a good Eastern Coop-
erative Oncology Group performance status (0/1:72/4). The
histologic types included 37 (48.7%) squamous-cell carci-
noma, 28 (36.8%) adenocarcinomas, and 11 (14.5%) large-
cell carcinomas. There were 20 patients (26.3%) with stage I,
40 (52.6%) with stage II, 11 (14.5%) with stage IIIA, and 5
(6.6%) with stage IIIB (T4) NSCLC. Sixty-eight patients
were treated with surgery alone, 4 with stage IIIA had
postoperative radiotherapy, 2 with IIIB had chemotherapy,
and 2 with stage IIIB had chemotherapy and radiotherapy.
At a median follow-up time of 23 months, 51 patients
(67.1%) were alive (46 pts free of cancer and 5 with recur-
rence), 25 patients (32.9%) died. In 18 cases (23.6%) death
was caused by disease progression, and in 7 cases (9.2%),
death was due to a nontumor-related cause. Twenty-three of
76 pts (30.2%) had recurrent disease: 9 pts relapsed locally
and 14 had distant metastases.
Sixty-six matched blood donors had a median age of 65
years, ranging from 56 to 75 years; 89.4% were males and
90.9% were smokers.
Table 1 shows the clinical-pathologic characteristics of
both patients and controls.
Plasma DNA Levels in Cancer Patients and
Controls
In all 76 patients, mean value of plasma DNA concen-
tration was 60 ng/ml (SD: 99.8), significantly different from
the mean amount of 5 ng/ml (SD: 8.8) observed in 66 controls
(mean difference, 54.7; 95% CI: 79.1–30.3; t test  4.76;
76.3 df; p  0.0001). Moreover, DNA levels were found
higher than DNA levels of controls (mean difference, 54.4;
95% CI: 78.1–30.6; t test  4.35; 59.9 df; p  0.0001),
when only stage I–II patients were considered.
The ROC AUC shown in Figure 2 was 0.82 (95% CI:
0.75–0.88), suggesting a good discrimination power of the
molecular assay. The highest accuracy was obtained at the
cut-off point of 3.25 ng/ml corresponding to a sensitivity and
specificity of 80% and 61%, respectively. Considering this
cut-off value, 61 of 76 (80.0%) patients had high circulating
DNA levels. No statistically significant effect of age, sex,
smoking status, histology, or tumor stage on plasma DNA
concentration was observed.
Prognostic Value of Circulating Plasma DNA
Levels
Baseline levels of circulating DNA did not seem to
correlate with patients prognosis, in terms of DFS (HR 
0.62; 95% CI: 0.27–1.45; p  0.27) and OS (HR  0.79;
95% CI: 0.29–2.11; p 0.63). Plasma DNA levels were also
detected at the 3rd and 12th months (1.5 month) after
surgery in 57 of cancer patients. A statistically different trend
of DNA levels during time in patients without relapse, or who
relapsed within 3 months and within 12 months was detected
(F  10.8; 1 and 80 df; p  0.0015). In fact, in pts without
recurrence, mean circulating DNA was decreasing: it was
48.5 ng/ml (SD: 75.4) at baseline, 32.8 ng/ml (SD: 59.3) at
the 3rd month, and 20.6 ng/ml (SD 25.8) at the 12th month
after surgery. In 21 pts who relapsed, mean circulating DNA
at baseline was 97.1 ng/ml (SD: 140.7). Mean circulating
DNA was different between patients who relapsed within or
after 3 months from surgery. In nine patients who relapsed
within 3 months after surgery, baseline mean level was 76.6
ng/ml (SD: 137.0) and increased to 292.7 ng/ml (SD: 530.9)
TABLE 1. Characteristics of NSCLC Patients and Controls
Characteristics N Percent
NSCLC patients 76 100
Median age (yr), range 68 (42–86)
Sex
Male 65 85.5
Female 11 15.5
Smoking history
Former/current smoker 69 90.8
Never smoker 7 9.2
Histology
SCC 37 48.7
ADC 28 36.8
LCC 11 14.5
Stage
I 20 26.3
II 40 52.6
IIIA 11 14.5
IIIB 5 6.6
Resection
Pneumonectomy 8 10.6
Lobectomy 66 86.8
Wedge 2 2.6
Subject controls 66 100
Median age (yr), range 65 (56–75)
Sex
Male 59 89.4
Female 7 10.6
Smoking history
Former/current smoker 60 90.9
Never smoker 6 9.1
ADC, adenocarcinomas; SCC, squamous-cell carcinomas; LCC, large-cell
carcinomas.
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at 3rd month being at that time significantly higher when
compared with mean level of patients with no evidence of
disease (F  11.2, 1 and 49 df; p  0.0016). In pts with
recurrence after 3 months, mean baseline circulating DNA
was 91.5 ng/ml (SD: 152.0), decreased to 25.0 ng/ml (SD:
37.5) at the 3rd month, and again increased to 70.4 ng/ml (SD:
91.1) at time of recurrence. In seven patients who relapsed at
12 months (1.5 month) after surgery, mean DNA level at
that time was detected higher when compared with mean
level of 26 patients with no evidence of disease (F  0.44; 1
and 49 df; p 0.511). Figure 3 shows the trend of circulating
plasma DNA levels of each patient, according to relapse
status.
Frequency of MA and p53 Mutation in
Tumor DNA
The frequency of MA and p53 mutations in tumor DNA
samples according to main clinical-pathologic features is
shown in Table 2.
MA in at least one locus was found in 39.5% (30 of 76)
of NSCLC tumors; shift (microsatellite instability) was de-
tected in 36.6% (11 of 30) and LOH was found in 63.4% (19
of 30) tumors.
In particular, MA (LOH or shift) at D3S1289, D3S1266,
D3S2338, D3S1300 (FHIT) were observed in 17.1% (13 of 76),
14.5% (11 of 76), 11.8% (9 of 76), and in 30.3% (23 of 76)
patients, respectively.
MA occurred in 56.8% (21 of 37) squamous-cell cancer
tumors compared with 17.9% (5 of 28) adenocarcinomas and
36.4% (4 of 11) large-cell carcinoma (2  10.01; 2 df; p 
0.007). In tumor samples, MA was also significantly higher in
smokers than in nonsmokers (Fisher exact test F  0.0245,
p  0.037). No statistically significant association was found
with age, gender, ECOG-performance status, weight loss,
grading, lymph node involvement, and stage.
P53 genomic mutations were observed in 54.0% (41 of
76) tumor DNA samples. In particular, single mutations were
observed in exon 5 in 15.8% (12 of 76) cases, in exon 6 in
7.8% (6 of 76), in exon 7 in 18.4% (14 of 76), and in exon 8
in 22.4% (17 of 76). The copresence of p53 mutations and
MA in tumor samples was observed in 63.2% (48 of 76) of
patients. P53 occurred in 67.6% (25 of 37) squamous-cell
cancer tumors compared with 35.7% (10 of 28) of adenocar-
cinomas and 64.5% (6 of 11) large-cell carcinomas (2 
6.42; 2 df; p  0.04). P53 mutations were present in 75.0%
(12 of 16) of patients with stage pIII and in 48.3% (29 of 60)
with stage pI–II (2  3.57; p  0.059) and were associated
with lymph node involvement (2 test for trend  6.38; p 
0.012). P53 as MA were more frequently detected in smokers
than in nonsmokers (2  4.88; p  0.027). There was no
association between p53 mutations and grading, ECOG-
performance status, weight loss, age, and gender.
FIGURE 2. Receiver-operating characteristics plot from
comparison of normal subjects versus NSCLC group.
FIGURE 3. Distribution of DNA
level at patient follow-up according
to relapse status.
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Association among Biologic Variables
Analysis of association among biologic variables
showed that p53 mutations were significantly associated with
MA (odds ratio  5.1; 95% CI: 1.8–14.4; 2  10.2; p 
0.001); 23 of 30 pts (76.7%) with MA had p53 mutations.
Microsatellite alterations were also significantly associated
with higher levels of circulating DNA (evaluated as a con-
tinuous variable) (t test  3.35; p  0.0013). No association
between p53 mutations and levels of circulating DNA was
observed (t test  1.78; p  0.078).
Prognostic Value of MA and P53 Mutations in
Tumor DNA
Of 30 pts identified for MA, 15 (50.0%) recurred or
died compared with 15 of 46 (32.6%) without MA (HR 
2.2; 95% CI: 1.1–4.6; p  0.033) (Figure 4A, Table 3). Forty
percent (12 of 30) of the pts with MA at four loci died after
surgery compared with 28.3% (13 of 46) of the pts without
MA (HR  2.1; 95% CI: 0.9–4.7; p  0.075).
At median follow-up time of 23 months, among 41 pts
with tumor p53 gene mutations, 48.8% pts (20 of 41) died
compared with 14.3% (5 of 35) pts without p53 gene muta-
tion (HR  2.3; 95% CI: 0.8–6.6; p  0.11).
When the DFS rate was considered, 58.5% (24 of 41) of
the pts with p53 mutations relapsed or died compared with
17.1% (6 of 35) of the pts without p53 mutations (HR  2.9;
95% CI: 1.1–7.5; p  0.026) (Figure 4B, Table 3).
DISCUSSION
In our study, we have analyzed critical chromosomal
loci at 3p14 (D3S1300 FHIT locus), 3p23 (D3S1266), 3p21
(D3S1289), and at 3p24.2 (D3S2338), which are hot-spot
deletions most frequently present in lung cancer. The aim of
the study was to evaluate if MA, p53, and circulating DNA in
early-stage NSCLC may be associated with the different
biologic behavior of tumors and therefore different patient
outcome. The choice of the three genetic targets, p53, FHIT,
and 3p loci, was motivated by the consensus that these
changes are the most frequent and earliest alterations in lung
carcinogenesis, thus fulfilling the criteria for optimal biomar-
kers. Microsatellite alterations have been frequently detected
at multiple chromosomal loci in NSCLC tumor samples. It is
believed that MA inactivate critical tumor suppressor genes
and plays an important role in tumor initiation and progres-
sion. Recent studies have suggested a potential prognostic
value of MA at certain chromosomal loci in NSCLC.7,8 In
particular, MA at chromosome 2p and 3p have been associ-
ated with poor survival in stage I NSCLC.9 Moreover, the
markers analyzed are located within a gene (FHIT). In fact,
previous studies have shown that loss of 3p14 can frequently
be found even in the non-neoplastic bronchial epithelium of
smokers23 and in preneoplastic lesions associated with lung
cancers.24,25 In our pilot study, we observed 40% MA fre-
quency in at least one locus on 3p. This frequency appears
lower with respect to that found by some other authors12
probably due to the selection of different chromosomal sub-
regions or a different patient population. MA were found
associated with squamous histotype, p53 mutations, and were
more frequent in smokers. Our study suggests that MA at four
loci at 3p locus independently predict poor outcome in terms
of disease-free survival.
Our results fit with those reported by Burke et al.26 who
has found that MA at the FHIT locus at 3p14.2 (D3S1300 and
D3S1234) in resected stage pI–II NSCLC was associated
with p53 missense mutations, nonadenocarcinoma histology,
and poor survival (P  0.01) independently of tumor stage.
TABLE 2. Frequency of p53 Mutations and MA in Tumor DNA Samples According to
Main Clinical-Pathologic Features (n  76)
Characteristics
p53 Mutations Microsatellite Alterations
N Percent p N Percent p
Sex
Male 36/65 55.4 27/65 41.5
Female 5/11 45.4 0.54 3/11 27.3 0.37
Smoking status
Former/current smoker 40/69 58.0 30/69 43.5
Never smoker 1/7 14.3 0.027 0/7 0 0.037
Type
SCC 25/37 67.6 21/37 56.8
ADC 10/28 35.7 0.04 5/28 17.9 0.007
LCC 6/11 64.5 4/11 36.4
pN status
pN0 22/51 43.1 20/50 39.2
pN1 9/12 75.0 0.012 6/12 50.0 0.76
pN2 10/13 76.9 4/13 30.7
Stage
I–II 29/60 48.3 25/60 41.7
III 12/16 75.0 0.059 5/16 31.2 0.45
ADC, adenocarcinomas; SCC, squamous-cell-carcinomas; LCC, large-cell carcinomas.
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Horio et al.27 in resected NSCLCs has found a trend toward
poorer prognosis for 3p LOH. Mitsudomi et al.28 has also
found an increased frequency of 3p LOH in resected NSCLC
with squamous histology when compared with adenocarcino-
mas. Some other authors9,10,29,30 did not observed a statisti-
cally significant association between MA at 3p locus and OS
probably due to the lower sample size and/or differences in
the analyzed loci.
FIGURE 4. Kaplan-Meier disease-free survival curves for 76 NSCLC patients evaluated according to tumor: (A) microsatellite
alterations; (B) p53 mutations. MA, microsatellite alterations; wt, wild-type.
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In our study, 55% of the NSCLC had p53 mutations and
its frequency was higher in squamous-cell carcinomas and in
smokers than in adenocarcinomas and in nonsmokers as already
reported by Fong et al.31 Moreover, our results show that p53
mutations were associated with disease-free survival in NSCLC
patients as we have already observed in advanced NSCLC.32 A
summary of 14 studies on prognostic importance of p53 muta-
tions or overexpressions in resected NSCLC [mutational analy-
sis (4 studies); immunostaining (8 studies); and both techniques
(2 studies)] yielded controversial results.33 Aberrant p53 expres-
sion correlated with a shortened survival in 5 of 10 immunohis-
tochemical studies, improved survival in three studies, and had
no association with survival in two studies. In one study that
analyzed gene mutation and protein expression, only the latter
predicted shortened survival. Different results may be possible
the fact that different antibodies have been used as it was already
discussed above. Moreover, biologic significance of wild-type
p53 overexpression, immunohistochemically detectable in cer-
tain tumors, is unclear, and different p53 mutants might have
different effect in lung cancer.
The association between MA and p53 mutations ob-
served in the present study is consistent with the study of
Zienolddiny et al.34 The reason for this association is proba-
bly related to the fact that altered p53 function lead to
genomic instability and increased recombination, thereby
predisposing cells to events leading to allelic loss.
Analysis of circulating DNA in plasma is a promising
noninvasive diagnostic tool, requiring only a limited blood
sample. For this study, we performed the real-time quantita-
tive PCR assay, using the human telomerase reverse tran-
scription (hTERT) gene as an indicator of the global amount
of circulating DNA in plasma. We show that this assay has
good sensitivity and specificity, as estimated by the AUC
ROC curve, suggesting that this method may discriminate
NSCLC patients from healthy individuals. Our findings are in
agreement with those reported by Sozzi et al.35 who showed
a higher plasma DNA concentration in 84 lung cancer pa-
tients compared with 43 controls, regardless of tumor stage.
We found increased amounts of circulating plasma DNA in
samples from all stages. This is particularly relevant for small
lesions, the systematic detection of which could help reduce
lung cancer morbidity and mortality. One important aspect of
our quantitative analysis was the ability to follow longitudinal
changes after cancer resection. The data showed a decrease of
circulating DNA values after lung resection. We found in-
creased levels of plasma DNA at baseline in patients with
recurrent disease, when compared with the cancer-free pa-
tients. These increased levels were more evident in patients
with proven disease relapse at 3 months from surgery when
compared with the cancer-free patients, suggesting that these
patients might have metastatic disease at diagnosis. In fact,
these patients had more often developed multiple visceral
metastases as site of recurrence, whereas there was no statis-
tically significant difference in the values of plasma DNA
between the patients with recurrence at 12th month after
surgery and the patients with no evidence of disease even if
there was a trend toward increase of circulating DNA over
time. Moreover, these patients had lung recurrence or re-
lapsed in nonvisceral sites such as bone metastases. This data
suggest that quantification of plasma DNA might be useful in
monitoring surgical patients during and after adjuvant ther-
apy. The analysis of MA and p53 in plasma DNA of our
series is the object of another ongoing study.
In conclusion, our data suggest that MA and p53
mutations detected in tumor DNA of NSCLC are associated
with DFS, correlate, and are more frequently detected in
squamous histology and in smokers. The analysis of circu-
lating DNA identifies patients with possible systemic disease
at diagnosis and might be proposed as an early detection test
of disease recurrence. These results will be validated in a
large-scale prospective study to improve classification of
early-stage NSCLC and identify these patients in which
aggressive treatment is needed.
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